A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2014

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

Daclatasvir

DRUG

Asunaprevir

DRUG

Ribavirin

BIOLOGICAL

pegIFNα-2b

DRUG

Telaprevir

Trial Locations (48)

1058470

Local Institution, Minato-ku

1138519

Local Institution, Bunkyo-ku

1138655

Local Institution, Bunkyo-ku

1428666

Local Institution, Shinagawa-ku

1808610

Local Institution, Musashino-shi

2138587

Local Institution, Kawasaki-shi

2360004

Local Institution, Yokohama

2608677

Local Institution, Chiba

3290498

Local Institution, Shimotsuke-shi

3380001

Local Institution, Saitama

3500495

Local Institution, Iruma-gun

3700829

Local Institution, Takasaki

3908621

Local Institution, Matsumoto

4093898

Local Institution, Chuo-shi

4102295

Local Institution, Izunokuni

4668560

Local Institution, Nagoya

4678602

Local Institution, Nagoya

4701192

Local Institution, Toyoake Shi

5008513

Local Institution, Gifu

5038502

Local Institution, Ogaki-shi

5400006

Local Institution, Osaka

5438555

Local Institution, Osaka

5458586

Local Institution, Osaka

5640013

Local Institution, Suita

5650871

Local Institution, Suita-shi

5898511

Local Institution, Osaka-sayama-shi

6028566

Local Institution, Kyoto

6348522

Local Institution, Kashihara

6638501

Local Institution, Nishinomiya-shi

7008558

Local Institution, Okayama

7340037

Local Institution, Hiroshima

8108563

Local Institution, Fukuoka

8140180

Local Institution, Fukuoka

8158555

Local Institution, Fukuoka

8300011

Local Institution, Kurume

8528501

Local Institution, Nagasaki

8568562

Local Institution, Ōmura

8608556

Local Institution, Kumamoto

8628655

Local Institution, Kumamoto

8795593

Local Institution, Yufu

8908520

Local Institution, Kagoshima

9188503

Local Institution, Fukui-shi

9808574

Local Institution, Sendai

9909585

Local Institution, Yamagata

080-0016

Local Institution, Obihiro-shi

0600033

Local Institution, Sapporo

0608648

Local Institution, Sapporo

760-8557

Local Institution, Takamatsu

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01718145 - A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects | Biotech Hunter | Biotech Hunter